New asthma drug tested in kids: could fasenra help?

NCT ID NCT06427876

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study looks at how safe and effective Fasenra (benralizumab) is for children aged 6 to 14 with severe asthma that isn't controlled by other treatments. Researchers will track side effects and measure lung function and asthma control in 40 children over time. The goal is to see how the drug works in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Fasenra (benralizumab) injection
What this could lead to: If successful, this study could confirm that Fasenra is safe and effective for children with severe asthma, offering a new treatment option.
What could go wrong: This is an observational study with only 40 children, so results may not apply to all patients. Side effects like serious infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRONCHIAL ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRONCHIAL ASTHMA

Contacts and locations

Locations

Research Site

Aichi, Japan
Research Site

Chiba, Japan
Research Site

Hiroshima, Japan
Research Site

Hokkaido, Japan
Research Site

Hyōgo, Japan
Research Site

Ibaraki, Japan
Research Site

Kumamoto, Japan
Research Site

Mie, Japan
Research Site

Okayama, Japan
Research Site

Osaka, Japan
Research Site

Saitama, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.